[ET Net News Agency, 28 January 2022] INNOVENT BIO (01801) fell 5.38% to HK$31.65.
It hits an intra-day low of HK$31.65, hitting a 52-week low, and an intra-day high of
HK$33.7. The total shares traded was 4.14 million, with a value of HK$134.59m. The active
buy/sell ratio is 47:53, with net selling turnover of HK$8.15m. MORGAN STANLEY HK SEC
accounts for greatest net responsive buying turnover of HK$12.56m, with volume weighted
average price of HK$32.446. CLSA LTD accounts for greatest net responsive selling turnover
of HK$23.03m, with volume weighted average price of HK$32.513. The stock has fallen a
combined 26.4% over the past 6 consecutive trading days.
The Hang Seng Index now fell 229 points, or 0.97% to 23,577; the Hang Seng China
Enterprises Index now fell 83 points, or 1.01% to 8,207; the Hang Seng TECH Index now fell
118 points, or 2.19% to 5,265; with an overall turnover of HK$66.96b.
The SSE Composite Index now rose 1 points, or 0.05% to 3,396, with an overall turnover
of RMB209.31b.
The SZSE Component Index now rose 71 points, or 0.53% to 13,470, with an overall
turnover of RMB140.32b.
Basic Information
=================
----------------------------------
Nominal 31.650 % Chg -5.38%
High 33.700 Low 31.650
Shares Tr 4.14m Turnover 134.59m
10-D SMA 39.280 %H.V 81.569
20-D SMA 40.880 VWAP 32.475
50-D SMA 53.513 RSI14 24.316
----------------------------------
Status: Hitting a 52-week low, active buy/sell ratio is 47:53, with net selling turnover
of HK$8.15m, falling a combined 26.4% over the past 6 consecutive trading days
Performance of stocks in the same sector or of relevance
========================================================
Stock (Code) Price (HK$) Change (%)
---------------------------------------------
INNOVENT BIO (01801) 31.65 -5.38
GENSCRIPT BIO (01548) 23.75 -4.81
ASCLETIS-B (01672) 3.76 -4.08
JUNSHI BIO (01877) 43.40 -5.65
JXR (01951) 7.36 -1.60
WUXI BIO (02269) 74.00 -4.14
TIGERMED (03347) 79.65 -1.24
BEIGENE (06160) 120.30 -9.48
AKESO-B (09926) 19.98 -5.53
REMEGEN-B (09995) 47.70 -4.41
---------------------------------------------
(ed)